Industry Experts

John earned his bachelor’s degree from Menlo College, an MS from Stanford University, a PhD from MD Anderson Cancer Center and post-doc’d at DNAX Research Institute and became a scientist at Schering Plough where he developed PEGylated IL-10 (AM0010) as an immunoncology asset. He then founded Targenics, later merged with ARMO Biosciences to clinically develop AM0010. ARMO Biosciences was acquired by Eli Lilly in 2018 for a $1.6B up front deal. Taking his learning from 30 years of small and large company experience, John started Deka Biosciences to build a platform that combines and targets cytokines to diseased tissues.